Last updated: September 8, 2026
Magnesium sulfate, potassium sulfate, and sodium sulfate are low-cost inorganic salts with two distinct pharmaceutical markets: hospital and emergency-care products sold as individual salts, and prescription bowel-preparation products sold as fixed combinations. The individual salts are largely generic and commodity-like. The highest-value pharmaceutical opportunity is in branded oral bowel preparations, including SUPREP and SUTAB, where formulation, dosage form, packaging, tolerability, and regulatory exclusivity matter more than the underlying salts.
What markets use magnesium sulfate, potassium sulfate, and sodium sulfate?
The three salts have different pharmaceutical roles.
| Ingredient |
Principal pharmaceutical uses |
Commercial profile |
| Magnesium sulfate |
Hypomagnesemia, eclampsia and preeclampsia, seizure prevention, torsades de pointes, laxative use |
Generic injectable and compounded hospital product; low unit price |
| Potassium sulfate |
Electrolyte replacement in limited settings; bowel cleansing when combined with other salts |
Limited standalone drug market; more valuable in proprietary bowel-prep combinations |
| Sodium sulfate |
Osmotic bowel cleansing, generally combined with potassium sulfate and magnesium sulfate |
Commercial value concentrated in branded bowel-prep products |
| All three together |
Colonoscopy preparation in oral tablet or oral solution products |
Main branded pharmaceutical opportunity |
Magnesium sulfate injection is an established hospital generic. FDA-approved labeling covers intravenous and intramuscular administration for magnesium deficiency and obstetric indications, subject to concentration and formulation.[1] Potassium sulfate and sodium sulfate have less commercial value as standalone prescription products because electrolyte replacement is usually addressed through broader potassium, sodium, or magnesium formulations.
The salts become commercially differentiated when used in an oral bowel-preparation system. SUPREP Bowel Prep Kit is an oral solution containing sodium sulfate, potassium sulfate, and magnesium sulfate. SUTAB is an oral tablet containing the same active salts in a solid dosage form.[2,3]
How large is the pharmaceutical market for these sulfate salts?
No reliable public source reports a consolidated global pharmaceutical market value for magnesium sulfate, potassium sulfate, and sodium sulfate as individual drug ingredients. Public company filings also generally do not disclose revenue by salt.
The addressable market divides into four segments:
- Generic hospital magnesium sulfate.
- Hospital and outpatient electrolyte products.
- Prescription oral bowel-preparation solutions.
- Prescription bowel-preparation tablets.
The first two segments are price-sensitive and fragmented. Manufacturing capacity, injectable quality systems, sterile filling, procurement contracts, and shortage management influence performance more than patent exclusivity.
The bowel-preparation segment has higher gross-margin potential. Branded products can command premium pricing because prescribers and patients value dosing convenience, lower preparation volume, tolerability, and tablet-based administration. The commercial tradeoff is a high pill burden for tablet products and the need to maintain adequate hydration.
SUPREP is marketed by Braintree Laboratories, a Sebela Pharmaceuticals company. SUTAB was developed and commercialized by Braintree and received FDA approval in December 2020.[3,4] Prescription bowel preparations compete with polyethylene glycol-electrolyte solutions, sodium picosulfate products, oral sulfate solutions, and generic versions of older preparations.
What is the FDA regulatory status of magnesium sulfate, potassium sulfate, and sodium sulfate products?
FDA regulatory status differs sharply by product.
Magnesium sulfate injection
Magnesium sulfate injection is marketed as a prescription generic drug in multiple concentrations and package formats. FDA labeling identifies intravenous and intramuscular administration and includes obstetric, electrolyte-replacement, and cardiac indications depending on the product label.[1]
The regulatory barriers are primarily manufacturing and quality barriers:
- Sterility assurance.
- Endotoxin control.
- Concentration accuracy.
- Container-closure integrity.
- Supply reliability.
- Compliance with current good manufacturing practice requirements.
These products generally do not have the same commercial protection associated with a new chemical entity.
SUPREP Bowel Prep Kit
SUPREP is an FDA-approved prescription oral solution containing sodium sulfate, potassium sulfate, and magnesium sulfate. It is supplied as a two-bottle kit that is diluted with water before administration.[2]
Its regulatory value comes from the complete product system:
- Fixed active-ingredient concentrations.
- Oral solution formulation.
- Dilution instructions.
- Dosing schedule.
- Packaging and kit configuration.
- Clinical and labeling data supporting colon cleansing.
SUTAB
SUTAB is an FDA-approved prescription tablet bowel preparation containing sodium sulfate, magnesium sulfate, and potassium chloride-related electrolyte components as specified in the approved labeling. It is administered with substantial volumes of water before, during, and after dosing.[3]
SUTAB competes on dosage form rather than on a new active pharmaceutical ingredient. Its tablet presentation may improve portability and reduce the need to consume a large volume of flavored solution, but the patient still must ingest multiple tablets and substantial water.
What patents protect SUPREP and SUTAB?
The principal protection for these products is formulation, dosage form, manufacturing, packaging, and method-of-use protection rather than molecule-level protection.
Patent categories
Potentially relevant patent categories include:
- Fixed-ratio sulfate compositions.
- Oral tablet formulations.
- Low-volume or split-dose bowel-cleansing regimens.
- Manufacturing methods for compressed sulfate tablets.
- Stability and moisture-control systems.
- Kits and packaging configurations.
- Colonoscopy-preparation methods.
A patent search must distinguish between patents listed in the FDA Orange Book and broader patent-family members that may not be listed against the approved product. Patent status also depends on jurisdiction, terminal disclaimers, patent-term adjustment, pediatric exclusivity, reexamination, post-grant proceedings, and claim scope.
The core sulfate ingredients are old, well-known compounds. New-product value therefore depends on whether claims cover a commercially necessary combination or process. A competitor may avoid a patent by changing the salt ratio, tablet architecture, excipients, dosing schedule, or manufacturing process, subject to FDA approval and clinical comparability.
What is the Orange Book status of SUPREP and SUTAB?
SUPREP and SUTAB are prescription drug products associated with FDA-approved new drug applications and may have Orange Book-listed patents depending on the relevant edition and product listing. The Orange Book is the controlling source for current patent listings, exclusivity codes, and expiration information.[5]
A current diligence review should separate:
- The active ingredient listing.
- The NDA holder.
- Listed patents.
- Use codes for method-of-use patents.
- Patent expiration dates.
- Pediatric exclusivity.
- Any delisted or expired patents.
- Litigation under the Hatch-Waxman Act.
Because the underlying sulfate salts are off-patent, an abbreviated new drug application applicant would focus on listed formulation, dosage-form, and method-of-use patents. A Paragraph IV certification could challenge one or more listed patents before their stated expiration.
When do magnesium sulfate, SUPREP, and SUTAB lose exclusivity?
Magnesium sulfate
Magnesium sulfate has no meaningful molecule-level exclusivity remaining. Competition is governed by ANDA approvals, manufacturing economics, procurement contracts, and supply availability.
SUPREP
SUPREP's commercial protection is associated with its approved formulation, label, patents, brand recognition, and prescriber familiarity. The relevant loss-of-exclusivity date cannot be reduced to the age of the sulfate ingredients. Generic entry depends on the expiration or successful challenge of applicable listed patents and FDA approval of an ANDA.
SUTAB
SUTAB received FDA approval in 2020, but approval date alone does not establish the end of patent protection. Its commercial protection may extend beyond standard regulatory exclusivity through formulation and tablet patents. FDA approval of a generic tablet would also require a product that satisfies pharmaceutical equivalence, bioequivalence, manufacturing, labeling, and quality requirements.
For investors, the key distinction is that salt obsolescence and branded-product loss of exclusivity are separate events. The salts are old. The dosage forms may retain protection.
Which companies are challenging sulfate bowel-preparation products?
Competitive pressure comes from several groups:
- Generic manufacturers developing oral sulfate solutions.
- Generic manufacturers developing tablet bowel preparations.
- Established bowel-preparation suppliers with polyethylene glycol products.
- Specialty pharmaceutical companies acquiring or licensing gastrointestinal assets.
- Contract manufacturers supplying private-label or regional products.
Publicly disclosed Paragraph IV litigation must be confirmed against current federal court dockets and FDA Orange Book records. A general market assessment should not treat every patent challenge as an imminent launch. Generic entry requires regulatory approval, commercial manufacturing capacity, sufficient inventory, and resolution of any injunction or settlement restrictions.
What patent litigation and settlement risks affect the market?
Patent disputes can affect branded bowel preparations in five ways:
- A Paragraph IV notice may trigger a 30-month FDA approval stay under the Hatch-Waxman framework.
- A patent owner may seek a preliminary injunction or permanent injunction.
- A settlement may establish a licensed or authorized-generic entry date.
- A court may narrow or invalidate formulation claims.
- An ANDA applicant may launch at risk before final resolution.
Settlement agreements can materially change the expected generic-entry date. The economically relevant terms may include entry timing, royalty obligations, supply arrangements, authorized-generic rights, and restrictions on dosage forms.
For magnesium sulfate injection, patent litigation risk is low relative to supply-chain risk. Product liability, recalls, sterile manufacturing failures, and shortages can have greater financial consequences than patent expiration.
How strong is the patent estate for these sulfate products?
| Product category |
Composition patent strength |
Formulation patent strength |
Manufacturing barrier |
Generic-entry risk |
| Magnesium sulfate injection |
Low |
Low to moderate |
Moderate to high |
High once supply is available |
| Sodium sulfate oral solution |
Low for ingredient |
Moderate |
Moderate |
Moderate to high |
| SUPREP-type solution |
Low for salts |
Moderate |
Moderate |
Moderate |
| SUTAB-type tablet |
Low for salts |
Moderate to high |
High relative to solution |
Moderate |
| Hospital electrolyte products |
Low |
Low |
Moderate |
High |
SUTAB has a potentially stronger commercial moat than a basic oral solution because tablet compression, dissolution, moisture control, packaging, tolerability, and bioequivalence may create technical barriers. Those barriers do not guarantee durable protection. A generic manufacturer can pursue a different formulation or dosage form if it can obtain FDA approval.
What manufacturing and intellectual-property barriers exist?
The most important barriers are operational.
Sterile magnesium sulfate
Manufacturers must maintain validated sterile processes, reliable raw-material supply, suitable vial or bag systems, and a compliant quality organization. Injectable magnesium sulfate can be commercially attractive during shortages, but pricing can fall quickly when additional suppliers enter.
Oral sulfate solutions
Solutions are easier to manufacture than compressed tablets but require control of:
- Active concentration.
- Osmolality.
- Taste and palatability.
- Stability.
- Container compatibility.
- Dilution instructions.
- Microbial quality.
Sulfate tablets
Tablet products require specialized control of:
- High active load.
- Compression behavior.
- Tablet size and swallowability.
- Dissolution.
- Friability.
- Moisture exposure.
- Packaging integrity.
- Patient adherence.
These factors can delay generic development even where composition patents are weak.
How does the financial trajectory differ by product?
Generic magnesium sulfate
The financial trajectory is volume-driven. Revenue depends on hospital demand, tenders, shortages, supplier exits, and manufacturing utilization. Margin expansion is difficult without a supply disruption or differentiated presentation.
Branded oral sulfate solutions
The trajectory depends on prescription volume, reimbursement, direct contracting, promotional spending, and generic substitution. Brand equity and physician familiarity can support pricing, but payers may shift volume to lower-cost preparations.
Branded sulfate tablets
Tablet products have the highest potential for premium pricing among the three categories. Revenue growth depends on adoption by gastroenterologists, ambulatory surgery centers, endoscopy networks, and patients who prefer tablets. The principal risks are high pill burden, payer restrictions, generic tablet entry, and competing low-cost solutions.
Revenue exposure
Manufacturers generally do not report revenue by magnesium sulfate, potassium sulfate, or sodium sulfate. Product-level exposure must therefore be estimated from prescription data, wholesaler sales, company filings, product-market share reports, and transaction disclosures. A company with a branded bowel-preparation portfolio has materially higher exposure to patent and generic-entry risk than a company selling hospital magnesium sulfate.
What generic launch scenarios exist?
Scenario 1: Solution-only entry
A generic oral sulfate solution reaches the market before a comparable tablet. It pressures SUPREP pricing but may not fully displace SUTAB.
Scenario 2: Tablet entry
An approved generic tablet directly challenges SUTAB. This scenario creates the greatest risk to branded tablet revenue because it competes on the same dosage form.
Scenario 3: Authorized-generic launch
The brand owner licenses or supplies an authorized generic. The company preserves manufacturing economics while reducing third-party generic erosion.
Scenario 4: Staggered market entry
Separate entrants launch solution and tablet products at different times. Prescribers may continue using the brand with the stronger adherence profile or better payer access.
How does this market compare with polyethylene glycol bowel preparations?
Polyethylene glycol products usually have stronger price competition and broad generic availability. Sulfate preparations can differentiate through lower solution volume, tablet convenience, and prescribing familiarity.
| Factor |
Sulfate bowel preparations |
Polyethylene glycol preparations |
| Active ingredients |
Sodium, potassium, and magnesium sulfate combinations |
PEG with electrolyte systems |
| Main differentiation |
Volume, dosage form, taste, tablet convenience |
Established efficacy, broad availability, price |
| Patent value |
Formulation and dosage form |
Usually limited for legacy generic products |
| Generic pressure |
Significant but product-specific |
High |
| Premium pricing potential |
Higher for branded tablets |
Lower for standard solutions |
| Manufacturing complexity |
Higher for high-load tablets |
Variable, often lower for established solutions |
Key Takeaways
- Magnesium sulfate injection is a mature generic market with limited patent protection and meaningful sterile-manufacturing risk.
- Potassium sulfate and sodium sulfate have limited standalone pharmaceutical value.
- The main branded opportunity is the fixed combination of sulfate salts used for colonoscopy preparation.
- SUPREP and SUTAB derive protection from formulation, dosage form, packaging, labeling, and related patents, not from novel salt molecules.
- SUTAB has a stronger technical differentiation profile than a standard oral sulfate solution because high-load tablet manufacturing is more demanding.
- FDA Orange Book listings and current federal litigation records are essential for determining actual generic-entry timing.
- Generic entry can occur through a solution, tablet, authorized generic, or staggered product strategy.
- Public companies generally do not disclose revenue by individual sulfate salt, so financial exposure must be assessed at the product or business-segment level.
- Manufacturing reliability, reimbursement, payer control, and patient adherence may matter more than molecule-level intellectual property.
- The market's long-term financial trajectory is likely to favor efficient generic supply for injectable magnesium sulfate and differentiated, but increasingly price-sensitive, branded bowel-preparation products.
FAQs
Is magnesium sulfate still patent protected?
The magnesium sulfate molecule is long established and does not have meaningful molecule-level patent protection. Product-specific patents may apply to specialized formulations, delivery systems, or manufacturing processes.
Are sodium sulfate and potassium sulfate active pharmaceutical ingredients?
They can be active ingredients in approved drug products, particularly oral bowel preparations. Their commercial value depends on the finished formulation rather than the isolated salts.
Is SUTAB a generic version of SUPREP?
No. SUTAB and SUPREP contain sulfate-based bowel-preparation ingredients but use different dosage forms. SUTAB is a tablet product, while SUPREP is an oral solution kit.
What is the main risk to branded sulfate bowel-preparation revenue?
The main risk is approved generic entry, particularly a generic product with the same dosage form. Payer substitution and lower-cost competing bowel preparations also pressure revenue.
Can a generic manufacturer avoid sulfate-product patents?
Potentially. An ANDA applicant may design around formulation or process claims, challenge listed patents through a Paragraph IV certification, or wait for patent expiration. The outcome depends on the claims, FDA requirements, and litigation.
References
- U.S. Food and Drug Administration. (2024). Magnesium sulfate injection prescribing information.
- U.S. Food and Drug Administration. (2024). SUPREP bowel prep kit prescribing information. Braintree Laboratories, Inc.
- U.S. Food and Drug Administration. (2024). SUTAB prescribing information. Braintree Laboratories, Inc.
- U.S. Food and Drug Administration. (2020, December 10). FDA approves new tablet formulation for colonoscopy preparation.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
